INSIGHT MM: A large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
Por:
Costello C., Davies F.E., Cook G., Vela-Ojeda J., Omel J., Rifkin R.M., Berdeja J., Puig N., Usmani S.Z., Weisel K., Zonder J.A., Terpos E., Spencer A., Leleu X., Boccadoro M., Thompson M.A., Romanus D., Stull D.M., Hungria V.
Publicada:
1 ene 2019
Resumen:
With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. © 2019 Future Medicine Ltd.
Filiaciones:
Costello C.:
Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, San Diego, CA 92093, United States
Davies F.E.:
Myeloma Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, United States
Cook G.:
Department of Haematology, Leeds Cancer Centre, St James's University Hospital, Leeds, United Kingdom
Vela-Ojeda J.:
Hematology Department, La Raza Medical Center, IMSS, México City, Mexico
Omel J.:
Central Nebraska Myeloma Support Group, Grand Island, NE 68801, United States
Rifkin R.M.:
Department of Hematology Research, US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO 80218, United States
Berdeja J.:
Department of Hematology, Sarah Cannon Research Institute, Nashville, TN 37203, United States
Puig N.:
Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
Usmani S.Z.:
Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC 28204, United States
Weisel K.:
Department of Hematology, University of Tuebingen, Tuebingen, Germany
Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Zonder J.A.:
Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, United States
Terpos E.:
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Spencer A.:
Department of Clinical Haematology, Alfred Health-Monash University, Melbourne, VIC, Australia
Leleu X.:
Pôle Régional de Cancérologie, CIC1402 INSERM, CHU de Poitiers, France
Boccadoro M.:
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
Thompson M.A.:
Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI 53215, United States
Romanus D.:
Global Outcomes Research, Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, United States
Stull D.M.:
Global Medical Affairs, Millenium Pharmaceuticals, Inc., Cambridge, MA 02139, United States
Hungria V.:
Department of Hematology, Clinica São Germano, Santa Casa Medical School, São Paulo, Brazil
|